Abstract
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are on a spectrum of a rare and potentially fatal immune-mediated mucocutaneous disease. As mortality rates decrease, more survivors are left with chronic complications including those of the ocular surface. SJS/TEN can result in severe, debilitating ocular surface disease that can lead to corneal blindness. Ophthalmic care from the time of admission onwards is crucial in mitigating the acute and chronic manifestations of SJS/TEN. This chapter discusses the ocular manifestations of disease in the acute and chronic phases, systemic and topical treatment, and the future of care in SJS/TEN.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AMT:
-
Amniotic membrane transplantation
- BKP2:
-
Type 2 Boston keratoprosthesis
- IVIG:
-
Intravenous immunoglobulin
- LSCD:
-
Limbal stem cell deficiency
- MMG:
-
Mucous membrane graft
- MOOKP:
-
Modified osteo-odonto-keratoprosthesis
- OSDI:
-
Ocular surface disease index
- PED:
-
Persistent epithelial defects
- PROSE:
-
Prosthetic replacement of the ocular surface ecosystem
- SCORTEN:
-
SCORe of toxic epidermal necrolysis
- SJS:
-
Stevens-Johnson syndrome
- TEN:
-
Toxic epidermal necrolysis
References
Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43–7.
Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome.An epidemiologic study from West Germany. Arch Dermatol. 1991;127:839–42.
Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, et al. Epidemiology of erythema exsudativummultiformemajus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769–73.
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J InvestigDermatol. 2016;136(7):1387–97.
Roujeau J, Kelly J, Naldi L, Rzany B, Stern R, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–8.
Sharma V, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J DermatolVenereolLeprol. 2008;74(3):238–40.
Chantaphakul H, Sanon T, Klaewsongkram J. Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. ExpTher Med. 2015;10(2):519–24.
Mockenhaupt V, Dunant N, Halevy B, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: results on drug risks based on the EuroSCAR-study. J InvestigDermatol. 2005;125(3):A76.
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.
Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Stevens–Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539–43.
Dodiuk-Gad R, Chung W, Valeyrie-Allanore L, Shear N. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J ClinDermatol. 2015;16(6):475–93.
Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26:33–41.
Magina S, Lisboa C, Leal V, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207:33–6.
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am AcadDermatol. 2013;69:187.e1–18716. quiz 203–4.
Kohanim S, Palioura S, Saeed HN, et al. Acute and chronic ophthalmic & involvement in Stevens – Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II Ophthalmic disease. Ocul Surf. 2016;14:168–88.
Lopez-Garcia JS, Rivas Jara L, Garcia-Lozano CI, et al. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology. 2011;118:265–71.
Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145:157–62.
Morales ME, Purdue GF, Verity SM, et al. Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150:505–510.e1.
Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26:123–9.
Chow L, Shih K, Chan J, Lai J, Ng A. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. BMC Ophthalmol. 2017;17(1):1–7.
Saeed HN, Chodosh J. Ocular manifestations of Stevens–Johnson syndrome and their management. Curr Opin Ophthalmol. 2016;27(6):522–9.
Ang AY, Palmon FE, Holland EJ. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis-30. In: Ocular surface disease: cornea, conjunctiva and tear film; 2013. p. 231–41.
Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg. 2007;33:1644–6.
Sachdev R, Bansal S, Sinha R, et al. Bilateral microbial keratitis in highly active antiretroviral therapy-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a case series. OculImmunolInflamm. 2011;19:343–5.
Alsuhaibani AH, Carter KD, Abramoff MD, Nerad JA. Utility of meibography in the evaluation of meibomian glands morphology in normal and diseased eyelids. Saudi J Ophthalmol. 2011;25:61–6.
Iyer G, Srinivasan B, Agarwal S, Kamala Muralidharan S, Arumugam S. Comprehensive approach to ocular consequences of Stevens Johnson syndrome – the aftermath of a systemic condition. Graefes Arch Clin Exp Ophthalmol. 2014;252(3):457–67.
Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS. Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol. 2018;189:17–28.
Catt H, Fish M, Ali. Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol. 2016;166:68–75.
Choi SH, Kim MK, Oh JY. Corneal limbal stem cell deficiency in children with stevens-johnson syndrome. Am J Ophthalmol. 2019;199:1–8. https://doi.org/10.1016/j.ajo.2018.10.016.
De Rojas M, Dart J, Saw V. The natural history of Stevens–Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91(8):1048–53.
Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol. 1973;90:376–9.
Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112:904–12.
Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.
Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
Heur M, Bach D, Theophanous C, Chiu GB. Prosthetic replacement of the ocular surface ecosystem scleral lenstherapy for patients with ocular symptoms of chronic Stevens-Johnson syndrome. Am J Ophthalmol. 2014;158(1):49–54.
Papakostas TD, Le HG CJ, Jacobs DS. Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with ahistory of Stevens–Johnson syndrome/toxic epidermal necrolysis. Ophthalmology. 2015;122(2):248–53.
Kaido M, Yamada M, Sotozono C, Kinoshita S, Shimazaki J, Tagawa Y, et al. The relation between visual performance and clinical ocular manifestations in Stevens-Johnson Syndrome. Am J Ophthalmol. 2012;154(3):499–511.e1.
Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102(11):1669–76.
Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson Syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160(2):228–237.e2.
Gregory D. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016;123(8):1653–8.
Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62(5):527–31.
Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. 2007;114(7):1294–302.
Chow L, Ng A, Chow S, Choy B, Shih K, Wong I, et al. A cross-sectional comparative study on chronic ocular manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series. Int Ophthalmol. 2018;38(3):1155–60.
Foster CS, Fong LP, Azar D, et al. Episodic conjunctival inflammation after Stevens–Johnson syndrome. Ophthalmology. 1988;95:453–62.
Chang V, Chodosh J, Papaliodis G. Chronic ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: the role of systemic immunomodulatory therapy. Semin Ophthalmol. 2016;31(1–2):178–87.
Kim KH, Park SW, Kim MK, Wee WR. Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome. Korean J Ophthalmol. 2013;27:331–40.
Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens- Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147:1004–11–11 e1.
Kim DH, Yoon KC, Seo KY, et al. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome. Ophthalmology. 2015;122:254–64.
Le HG, Saeed HN, Mantagos I, Mitchell C, Goverman J, Chodosh J. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: a survey. Burns. 2016;42(4):830–5.
Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009;116:685–90.
Tomlins PJ, Parulekar MV, Rauz S. “Triple-TEN” in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea. 2013;32:365–9.
Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995;14:473–84.
Kim JC, Tseng SC. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. Korean J Ophthalmol. 1995;9:32–46.
Mamede AC, Carvalho MJ, Abrantes AM, et al. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. 2012;349:447–58.
Zhou S, Chen J, Xu L, et al. Fresh amniotic membrane transplantation for conjunctival surface reconstruction. Yan KeXueBao. 1999;15:169–73.
Honavar SG, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. Ophthalmology. 2000;107:975–9.
John T, Foulks GN, John ME, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology. 2002;109:351–60.
Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;118:908–14.
Hsu M, Jayaram A, Verner R, et al. Indications and outcomes of amniotic membrane transplantation in the management of acute stevens-johnson syndrome and toxic epidermal necrolysis: a case-controlstudy. Cornea. 2012;31:1394–402.
Sotozono C, Inatomi T, Nakamura T, et al. Visual improvement after cultivated oral mucosal epithelial transplantation. Ophthalmology. 2013;120:193–200.
Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149:203–213.e2.
Sharma T, Kaur P, Khanna A, Vajpayee. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome: a randomized control trial: arandomized control trial. Ophthalmology. 2016;123(3):484–91.
Cai M, Zhang J, Guan L, Zhao M. Novel implantable composite biomaterial by fibrin glue and amniotic membrane for ocular surface reconstruction. J Mater Sci Mater Med. 2015;26(3):1–8.
Agrawal A, Pratap V. Amniotic membrane transplantation (AMT) without the use of sutures/fibrin glue. Nepalese J Ophthalmol: A Biannual Peer-reviewed Academic Journal of the Nepal Ophthalmic Society: NEPJOPH. 2015;7(14):173–7.
Kucukerdonmez C, Karalezli A, Akova Y, Borazan M. Amniotic membrane transplantation using fibrin glue in pterygium surgery: a comparative randomised clinical trial. Eye. 2010;24(4):558–66.
Kheirkhah C, Blanco L, Hayashida C, Tseng. Amniotic membrane transplantation with fibrin glue for conjunctivochalasis. Am J Ophthalmol. 2007;144(2):311–3.
Shanbhag SS, Chodosh J, Saeed HN. Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis. Ocul Surf. 2019;14(2). [Epub ahead of print].
Marinho DR, Burmann TG, Kwitko S. Labial salivary gland transplantation for severe dry eye due to chemical burns and Stevens-Johnson syndrome. OphthalPlastReconstrSurg. 2010;26:182–4.
Leibovitch I, Hoyama E, Limawararut V, et al. Novel technique to control hypersecretion from a transplanted autologous submandibular salivary gland for keratoconjunctivitissicca. Cornea. 2006;25:1251–3.
Sotozono C, Ueta M, Yokoi N. Severe dry eye with combined mechanisms is involved in the ocular sequelae of SJS/TEN at the chronic stage. Investig Ophthalmol Vis Sci. 2018;59(14):DES80–6.
Iyer G, Pillai VS, Srinivasan B, et al. Mucous membrane grafting for lid margin keratinization in Stevens-Johnson syndrome: results. Cornea. 2010;29:146–51.
Fu Y, Liu J, Tseng SC. Oral mucosal graft to correct lid margin pathologic features in cicatricial ocular surface diseases. Am J Ophthalmol. 2011;152:600–608.e1.
Sant’Anna AE, Hazarbassanov RM, de Freitas D, Gomes JA. Minor salivary glands and labial mucous membrane graft in the treatment of severe symblepharon and dry eye in patients with Stevens-Johnson syndrome. Br J Ophthalmol. 2012;96:234–9.
Haefliger IO, Vysniauskiene I, Pimentel AR, et al. Free autologous buccal mucosal graft transplantation to treat ocular complications after toxic epidermal necrolysis: case report. KlinMonatsblAugenheilkd. 2004;221:395–7.
Gurumurthy S, Iyer G, Srinivasan B, Agarwal S, Angayarkanni N. Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. Br J Ophthalmol. 2017;102(2):169–76.
Tougeron-Brousseau B, Delcampe A, Gueudry J, et al. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2009;148:852–859.e2.
Siqueira AC, Santos MS, Farias CC, et al. Scleral contact lens for ocular rehabilitation in patients with Stevens-Johnson syndrome. Arq Bras Oftalmol. 2010;73:428–32. Portuguese.
Parra AS, Roth BM, Nguyen TM, Wang L, Pflugfelder SC, Al-Mohtaseb Z. Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease. Ocul Surf. 2018;16(2):254–8.
Wang Y, Rao R, Jacobs DS, Saeed HN. Prosthetic replacement of the ocular surface ecosystem treatment for ocular surface disease in pediatric patients with Stevens-Johnson syndrome. Am J Ophthalmol. 2019;201:1–8.
Iyer G, Srinivasan B, Agarwal S, et al. Treatment modalities and clinical & outcomes in ocular sequelae of Stevens –Johnson syndrome over 25 years – a paradigm shift. Cornea. 2016;35:46–50.
Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratopros- thesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008;145:438–44.
Gomaa A, Comyn O, Liu C. Keratoprostheses in clinical practice – a review. Clin Exp Ophthalmol. 2010;38:211–24.
Durand ML, Dohlman CH. Successfulpreventionofbacterialendophthalmitis in eyes with the Boston keratoprosthesis. Cornea. 2009;28:896–901.
Rootman DB, Kim MJ, Aldave AJ, et al. Ocular surface, fornix, and eyelid rehabilitation in Boston type I keratoprosthesis patients with mucous membrane disease. OphthalPlastReconstrSurg. 2015;31:43–9.
De La Paz MF, De Toledo JA, Charoenrook V, et al. Impact of clinical factors on the long-term functional and anatomic outcomes of osteo-odonto-keratoprosthesis and tibial bone keratoprosthesis. Am J Ophthalmol. 2011;151:829–839.e1.
Basu S, Pillai V, Sangwan VS. Mucosal complications of modified osteo-odontokeratoprosthesis in chronic Stevens-Johnson Syndrome. Am J Ophthalmol. 2013;156(5):867–873.e2.
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: amarkerforStevens-Johnsonsyndrome. Nature. 2004;428:486.
Ueta M. Genetic predisposition to Stevens-Johnson syndrome with severe ocular surface complications. Cornea. 2015;34:S158–65.
Ueta M, Tokunaga K, Sotozono C, Sawai H, Tamiya G, Inatomi T, et al. HLA-A∗0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications (gene-geneinteraction between HLA-A∗0206 and TLR3). 2012;7(8):E43650.
Lee HS, Ueta MK, Kim MY, Seo KC, Sotozono C, Kinoshita S, Yoon K. Analysis of Ocular Manifestation and Genetic association of allopurinol-induced Stevens–Johnson Syndrome and toxic epidermal necrolysis in South Korea. Cornea. 2016;35(2):199–204.
Ueta MC, Kinoshita SK, Sawai HY, Tokunaga K, Shingaki R, Kawai Y, et al. Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. J Hum Genet. 2017;62(4):485–9.
Wakamatsu T, Ueta M, Tokunaga K. Human leukocyte antigen class I genes associated with Stevens-Johnson syndrome and severe ocular complications following use of cold medicine in a Brazilian population. JAMA Ophthalmol. 2017;135(4):355–60.
Kannabiran C, Ueta M, Sangwan V, Rathi V, Basu S, Tokunaga K, Kinoshita S. Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. Sci Rep (Nature Publisher Group). 2017;7(1):1–4.
Jongkhajornpong P, Lekhanont K, Pisuchpen P, Chantaren P, Puangsricharern V, Prabhasawat P, et al. Association between HLA-B∗44:03-HLA-C∗07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. Br J Ophthalmol. 2018;102(9):1303–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Saeed, H.N., Rashad, R. (2020). Ocular Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Colby, K., Dana, R. (eds) Foundations of Corneal Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-25335-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-25335-6_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-25334-9
Online ISBN: 978-3-030-25335-6
eBook Packages: MedicineMedicine (R0)